T<u></u>IN 6 9 N



 \backslash

MAXIMIZE CLOT RETENTION

TECHNOLOCY DESIGNED TO MIRCO-FILTRATION

THE DEVICE CAPTURE CLOT INSIDE

ΔΚΟΡ ΖΟΝΕ™ ΤΕCHNOLOCY TO UNIQUELY DESIGNED WITH

WITH ALL CLOT TYPES SUCCESS DESIGNED FOR FIRST-PASS SUCCESS

DROP ZONE THE CLOT INSIDE

Product Number	Description	Diameter (mm)	Working Lemgth (mm)	Total Basket Length (mm)	Push-wire Length (mm)	Number of Drop Zones	Minimum MC ID (Inches)
30020V-MS	NeVa 4.0 x 22 mm	4.0	22	39	180	2	0.021
Neva			$\langle \cdot \rangle$				
VN-4529-03RR	NeVa 4.5 x 29 mm	4.5	29	46	180	3	0.021
Neva		$\langle \cdot \rangle$	$\langle \rangle$				
VN-5537-03RR	NeVa 5.5 x 37 mm	5.5	37	56	180	3	0.027
Neva		$\langle \rangle$	$\langle \rangle$		\bigcirc		
VN-5537-03NR	NeVa NET 5.5 x 37 m	im 5.5	37	56	180	3	0.027
Neva	NET	Ó	\langle			•	





NEVA SUCCEEDED⁴

IMPRESSIVE FIRST PASS SUCCESS¹

SUCCESSFUL FIRST PASS RECANALIZATION: PERCENTAGE OF eTICI 2B-3 IN THE CLEAR STUDY (mITT, n = 107)





1. Core-lab adjudicated results from FDA-regulated IDE study NeVa CLEAR presented by Yoo A, et al. abstract 4311, ISC, Feb. 2023

HIGH EFFICACY DESIGN AGNOSTIC TO CLOT MORPHOLOGY^{2,4}

SUCCESSFUL IN REMOVING ALL CLOT TYPES²

NEVA RECANALIZATION RATES IN DIFFERENT CLOT MORPHOLOGIES



SUCCESSFUL WHERE OTHER DEVICES FAIL^{3,4}

SUCCESS RATE OF STENT RETRIEVERS WHEN INTERACTING WITH LARGE WHITE THROMBI ($\geq 6 \text{MM}$)

ALL TESTED DEVICES FAILED³

Solitaire* Trevo Embotrap Preset* Preset LT Catch* Eric Separator 3D

0% 60%

*These devices were able to minimally displace clots without removing them **The list of devices that failed to remove large white thrombi is incomplete

2. Results from animal model study: Ulm A.J. et al. Interventional Neurology 2018 ; 7 :205-2017 3 & 4. Results from in-vitro simulated thrombectomy studies: 3. Machi P, et al. JNIS. 2016; 0:1-7 and 4. Machi P, et al. Journal of Neuroradiology. April 2018

PROVEN SAFETY¹

COMPOSITE ENDPOINT OF 90-DAY ALL-CAUSE MORTALITY AND/OR 24-HOUR POST-PROCEDURE sICH (ITT, n = 139)



SIGNIFICANT CLINICAL OUTCOMES (90-DAY mRS \leq 2) IN THE CLEAR STUDY VERSUS PREDICATE STUDIES (mITT, n = 107)



1. Results from FDA-regulated IDE study NeVa CLEAR presented by Yoo A, et al. abstract 4311, ISC, Feb. 2023

MAXIMIZED RETENTION, MAXIMIZED REPERFUSION



SIGNIFICANTLY BETTER AT PREVENTING CLOT FRAGMENTS FROM EMBOLIZING DISTAL TERRITORIES^{5,6}

